Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roxro Files Rapid-acting Nasal Pain Spray

This article was originally published in The Pink Sheet Daily

Executive Summary

Specialty pharma reinvents generic ketorolac as hospital-strength pain med for short-term use at home.

You may also be interested in...



Allergan Promo For Acular LS Broadens Indications, FDA Warning Letter Says

Journal ad for the ophthalmic misleadingly suggests the drug is indicated for phacoemulsification, according to FDA.

Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?

Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel